S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
NASDAQ:PCSA

Processa Pharmaceuticals News Headlines

$4.35
-0.43 (-9.00%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.29
$5.04
50-Day Range
$4.03
$7.12
52-Week Range
$3.85
$14.24
Volume
19,072 shs
Average Volume
27,200 shs
Market Capitalization
$68.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.13
Get Processa Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Processa Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PCSA
News Sentiment

0.39

0.32

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PCSA Articles
This Week

3

0

PCSA Articles
Average Week



Processa Pharmaceuticals (NASDAQ:PCSA) News Headlines Today

SourceHeadline
finance.yahoo.com logoMultiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholders
finance.yahoo.com - January 17 at 5:06 PM
MarketBeat logoAnalyzing Processa Pharmaceuticals (NASDAQ:PCSA) and Turning Point Therapeutics (NASDAQ:TPTX)
americanbankingnews.com - January 16 at 6:10 AM
nasdaq.com logoProcessa Pharmaceuticals, Inc. Common Stock (PCSA)
nasdaq.com - January 13 at 7:40 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update
finance.yahoo.com - November 11 at 7:48 PM
nasdaq.com logoWhat You Need To Know About Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Investor Composition
nasdaq.com - November 2 at 1:59 AM
finance.yahoo.com logoProcessa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST
finance.yahoo.com - October 26 at 9:02 AM
finance.yahoo.com logoWhat Kind Of Shareholders Hold The Majority In Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Shares?
finance.yahoo.com - October 19 at 2:15 PM
finance.yahoo.com logoProcessa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
finance.yahoo.com - October 12 at 9:30 AM
sg.finance.yahoo.com logoProcessa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update
sg.finance.yahoo.com - September 16 at 11:10 AM
nasdaq.com logoProcessa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans
nasdaq.com - September 1 at 6:03 PM
finance.yahoo.com logoCompanies Like Processa Pharmaceuticals (NASDAQ:PCSA) Are In A Position To Invest In Growth
finance.yahoo.com - August 20 at 6:02 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
finance.yahoo.com - August 12 at 8:38 PM
ca.finance.yahoo.com logoOcuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
ca.finance.yahoo.com - August 12 at 10:37 AM
finance.yahoo.com logoProcessa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST
finance.yahoo.com - August 6 at 9:08 AM
finance.yahoo.com logoProcessa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
finance.yahoo.com - August 4 at 8:53 AM
finance.yahoo.com logoProcessa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
finance.yahoo.com - July 27 at 12:09 PM
sg.finance.yahoo.com logoPsirenity appoints new CEO and COO to accelerate delivery of mental health and wellness treatments
sg.finance.yahoo.com - July 7 at 5:42 PM
finance.yahoo.com logoProcessa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
finance.yahoo.com - July 6 at 10:14 AM
nasdaq.com logoDavid Young Is The Co-Founder of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) And Just Spent US$77k On Shares
nasdaq.com - June 25 at 6:52 PM
marketwatch.com logoInvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate in Access to Giving Virtual Investor Conference
marketwatch.com - June 23 at 7:50 PM
finance.yahoo.com logoPROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
finance.yahoo.com - June 17 at 9:22 AM
finance.yahoo.com logoProcessa Set to Join Russell Microcap® Index
finance.yahoo.com - June 8 at 12:44 PM
finance.yahoo.com logoProcessa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
finance.yahoo.com - June 7 at 7:57 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
finance.yahoo.com - May 20 at 7:13 PM
finance.yahoo.com logoRead This Before Selling Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares
finance.yahoo.com - May 20 at 2:13 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
finance.yahoo.com - May 13 at 8:40 PM
finance.yahoo.com logoProcessa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST
finance.yahoo.com - May 7 at 12:39 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
finance.yahoo.com - March 25 at 5:32 PM
finance.yahoo.com logoProcessa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
finance.yahoo.com - March 22 at 10:11 AM
finance.yahoo.com logoProcessa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica
finance.yahoo.com - March 17 at 9:53 AM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement
finance.yahoo.com - March 2 at 10:06 AM
marketwatch.com logoBioMedNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report
marketwatch.com - February 23 at 1:17 AM
finance.yahoo.com logoEncode Ideas, L.P. Announces the Initiation of Research Coverage on Processa Pharmaceuticals, Inc.
finance.yahoo.com - February 22 at 10:13 AM
finance.yahoo.com logoDo Institutions Own Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares?
finance.yahoo.com - February 19 at 11:46 AM
finance.yahoo.com logoProcessa Pharmaceuticals Announces $10.2 Million Strategic Financing
finance.yahoo.com - February 17 at 9:04 AM
finance.yahoo.com logoProcessa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
finance.yahoo.com - January 11 at 6:24 PM
realmoney.thestreet.com logoProcessa Pharmaceuticals, Inc. (PCSA)
realmoney.thestreet.com - December 9 at 8:46 PM
finance.yahoo.com logoProcessa Pharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 16 at 1:26 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update
finance.yahoo.com - November 12 at 6:30 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
finance.yahoo.com - November 5 at 3:13 PM
finance.yahoo.com logoProcessa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET
finance.yahoo.com - November 3 at 2:16 PM
markets.businessinsider.com logoProcessa Pharmaceuticals Closes $19.2 Million Public Offering
markets.businessinsider.com - October 8 at 9:37 AM
nasdaq.com logoNano-cap skin disease biotech Processa Pharmaceuticals prices Nasdaq uplisting at $4
nasdaq.com - October 2 at 12:04 PM
seekingalpha.com logoProcessa Pharma prices $19.2M public offering; uplisted to Nasdaq
seekingalpha.com - October 2 at 7:04 AM
nasdaq.com logoNano-cap skin disease biotech Processa Pharmaceuticals slashes valuation by 35% ahead of $16 million Nasdaq uplisting
nasdaq.com - September 30 at 10:44 PM
nasdaq.com logoSkin disease biotech Processa Pharmaceuticals lowers deal size ahead of $18 million Nasdaq uplisting
nasdaq.com - September 17 at 12:50 PM
finance.yahoo.com logoPROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR THE DEVELOPMENT OF ENILURACIL (PCS6422) FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL TUMORS
finance.yahoo.com - August 27 at 10:26 AM
seekingalpha.com logoProcessa Pharma in-licenses GI drug from South Korea's Yuhan
seekingalpha.com - August 20 at 1:38 PM
seekingalpha.com logoProcessa Pharma secures licensing deal with South Korea's GI disorder drug developer
seekingalpha.com - August 20 at 1:38 PM
finance.yahoo.com logoPROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS
finance.yahoo.com - August 20 at 1:38 PM
Get Processa Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.